DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection

Information source: Mashhad University of Medical Sciences
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Intraocular Pressure Change in Intravitreal Injection

Intervention: Timolol (Drug); Brimonidine (Drug); Acetazolamide (Drug); Mannitol (Drug); Placebo (Drug)

Phase: N/A

Status: Completed

Sponsored by: Mashhad University of Medical Sciences

Official(s) and/or principal investigator(s):
Nasser Shoeibi, M.D., Principal Investigator, Affiliation: Retina Research Center, Mashhad University of Medical Sciences, Mashhad, Iran


To assess the effect of prophylactic antiglaucoma agents in prevention of acute intraocular pressure rise after intravitreal injection.

Clinical Details

Official title: Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection: the Effect of Pretreatment With Antiglaucoma Agents

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Primary outcome: change in IOP

Detailed description: Acute intraocular pressure elevation after intravitreal injection of bevacizumab was proven. Acute intraocular pressure elevation most probably is volume related and long term intraocular pressure elevation relates to pharmacologic features of the medications which results in anatomic changes in the angle of anterior chamber. Numerous studies found an intraocular pressure elevation right after the injection and quick normalization within maximally 30 minutes. This intraocular pressure elevation which lasts about 30 minutes, can result in irreversible visual loss especially in patients with critical remaining nerve fibers in the optic nerve head, as occurs in glaucomatous patients. Is there any way to prevent or even shorten this time of intraocular pressure elevation? We tried in our study to find a suitable response for a question above, so we used several anti-glaucoma agents (Timolol, Brimonidine, Acetazolamide, Mannitol versus placebo) as a prophylaxis to prevent acute intraocular pressure elevation right after intravitreal bevacizumab injection.


Minimum age: 40 Years. Maximum age: 80 Years. Gender(s): Both.


Inclusion Criteria:

- all patients who candidate for receiving intravitreal bevacizumab

Exclusion Criteria:

- patients who had advanced glaucoma

- patients who received antiglaucoma agents in the past

- patients who had corneal scar which affect IOP measurement

Locations and Contacts

Retina Research Center, Khatam eye Hospital, Mashhad, Khorasan Razavi, Iran, Islamic Republic of
Additional Information

Starting date: February 2012
Last updated: May 13, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017